Clinical Psychopharmacology and Neuroscience indexed in CAS, DOI/Crossref, EMBASE, Korea Citation Index (KCI), KoreaMed, Korea Medical Citation Index (KoMCI), PubMed, PubMed Central (PMC), SCOPUS, SCI-expanded (SCIE), and Google Scholar:eISSN 2093-4327   pISSN 1738-1088

Cited by CrossRef (5)

  1. Mitsukuni Murasaki, Yoshifumi Inoue, Hiroshi Nakamura, Toshihiko Kinoshita. Long-term oral blonanserin treatment for schizophrenia: a review of Japanese long-term studies. Ann Gen Psychiatry 2021;20
    https://doi.org/10.1186/s12991-021-00361-3
  2. Dan Siskind, Erin Gallagher, Karl Winckel, Samantha Hollingworth, Steve Kisely, Joseph Firth, Christoph U Correll, Wade Marteene. Does Switching Antipsychotics Ameliorate Weight Gain in Patients With Severe Mental Illness? A Systematic Review and Meta-analysis. 2021;47:948
    https://doi.org/10.1093/schbul/sbaa191
  3. S. Chattopadhyay, U. Roy, S. Biswas, P. Roy, P. Mandal. Comparative Efficacy, Safety and Tolerability of Olanzapine and Blonanserin in Patients with Schizophrenia: A Parallel Group Study. 2021;48:45
    https://doi.org/10.2478/amb-2021-0023
  4. Shintaro Sakai, Yoshiro Morimoto, Yusuke Matsuzaka, Takeshi Nakano, Shinji Kanegae, Akira Imamura, Hiroki Ozawa. Switching from blonanserin tablets to blonanserin transdermal patches improves tardive dyskinesia: A case report. Neuropsychopharmacol Rep 2021;41:440
    https://doi.org/10.1002/npr2.12200
  5. Yoshifumi Inoue, Kimiko Tsuchimori, Hiroshi Nakamura. Safety and effectiveness of oral blonanserin for schizophrenia: A review of Japanese post-marketing surveillances. Journal of Pharmacological Sciences 2021;145:42
    https://doi.org/10.1016/j.jphs.2020.09.006